Jun 29, 2019
Clinical Trial: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relap...
Jun 28, 2019
This open-label, Phase 2 study is studying whether the monoclonal antibody Avelumab, in combination with radiation therapy, is...
FDA Accepts Application for New Engineered Toxin Body Drug by Takeda Oncology and Molecular Templ...
Jul 13, 2019
MUSCLES FOR MYELOMA
Bike the Coast 2019 Day 6: Keep Your Wheels Moving in Myeloma with Maintenance Therapy
Jun 27, 2019
Congratulations to Richard Hite, who successfully completed his 600 mile ride from San Francisco to San Diego in just 6 days! Richard rode to raise funds and awareness of multiple myeloma. Thank you Richard, your family and your amazing...
Clinical Trial: Daratumumab, Ixazomib, and Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed ...
May 23, 2019
A phase II study is open evaluating how well daratumumab, ixazomib, and dexamethasone work with or without bortezomib in treating patients with newly diagnosed multiple myeloma. Please not that for one of the patient groups, it will use two...
Find financial resources like housing, prescription and patient assistance programs and other helpful links that will guide you through your myeloma care.
Patients who are seen by myeloma specialists live longer. Find a myeloma specialists closest to you and add them to your care team for your best outcomes.
Today's myeloma therapies are yesterday's clinical trials and if more patients joined, we could accelerate a cure.Find a trial that's right for you using a myeloma clinical trial finder called SparkCures.
MYELOMA CROWD RESEARCH INITIATIVE
The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. The goal of the MCRI is to find and fund a cure for multiple myeloma.Learn More >
Thanks to our site sponsors: